Jolkinolide B alleviates renal fibrosis via anti-inflammation and inhibition of epithelial-mesenchymal transition in unilateral ureteral obstruction mice

Abstract Renal fibrosis is a critical pathological process lead to a progressive loss of renal function. Jolkinolide B (JB) is a natural compound with anti-inflammatory activity from Euphorbia fischeriana Steud. The study evaluated the effect of JB on renal fibrosis in mice with unilateral ureteral obstruction (UUO). The results showed that JB could decrease renal fibrotic area, reduce phosphorylation of NF-κB p65 and the release of TNF-α, IL-6 and IL-1β, restore the expression of vementin, α-SMA and E-cadherin, as well as TGF-β1 and p-smad2/3. In conclusion, JB might reduce renal fibrosis by inhibiting inflammation induced by NF-κB pathway and EMT mediated by TGF-β1/Smad pathway.

[1]  S. Zhuang,et al.  New Insights Into the Role and Mechanism of Partial Epithelial-Mesenchymal Transition in Kidney Fibrosis , 2020, Frontiers in Physiology.

[2]  H. Lan,et al.  Diverse Role of TGF-β in Kidney Disease , 2020, Frontiers in Cell and Developmental Biology.

[3]  A. Ortiz,et al.  Targeting the progression of chronic kidney disease , 2020, Nature Reviews Nephrology.

[4]  Philip D. Plowright.  Front , 2019, 2020 Fourth World Conference on Smart Trends in Systems, Security and Sustainability (WorldS4).

[5]  Ying-Yong Zhao,et al.  Chronic kidney disease: Biomarker diagnosis to therapeutic targets. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[6]  K. Karamchandani,et al.  169 , 2019, Critical Care Medicine.

[7]  R. Roman,et al.  Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets , 2018, European journal of pharmacology.

[8]  Maria João Pires,et al.  Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. , 2017, In vivo.

[9]  S. Allison,et al.  Fibrosis: Targeting EMT to reverse renal fibrosis , 2015, Nature Reviews Nephrology.

[10]  D. Kong,et al.  Protective effect of Jolkinolide B on LPS-induced mouse acute lung injury. , 2015, International Immunopharmacology.

[11]  Xiao-ming Meng,et al.  Inflammatory processes in renal fibrosis , 2014, Nature Reviews Nephrology.

[12]  Xiaobing Yu,et al.  Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways. , 2014, Biochemical and biophysical research communications.

[13]  J. Duffield,et al.  Myofibroblasts in Fibrotic Kidneys , 2013, Current Pathobiology Reports.

[14]  Y. Shoyama,et al.  17-Hydroxy-jolkinolide B, a diterpenoid from Euphorbia fischeriana, inhibits inflammatory mediators but activates heme oxygenase-1 expression in lipopolysaccharide-stimulated murine macrophages. , 2012, International immunopharmacology.

[15]  Yongxu Sun,et al.  Chemical Constituents and Biological Activities of Euphorbia fischeriana Steud. , 2011, Chemistry & biodiversity.

[16]  P. Kantharidis,et al.  The role of EMT in renal fibrosis , 2011, Cell and Tissue Research.

[17]  Hiroshi Yamamoto,et al.  Blockade of Endothelial-Mesenchymal Transition by a Smad3 Inhibitor Delays the Early Development of Streptozotocin-Induced Diabetic Nephropathy , 2010, Diabetes.

[18]  S. Klahr,et al.  Obstructive nephropathy and renal fibrosis. , 2002, American journal of physiology. Renal physiology.

[19]  H. Nakshatri,et al.  Repression of transforming-growth-factor-β-mediated transcription by nuclear factor κB , 2000 .